Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inverness closes Cholestech buy:

This article was originally published in Clinica

Executive Summary

Inverness Medical Innovations (IMI) has completed its acquisition of the heart disease diagnostics specialist Cholestech in a stock-for-stock merger. The deal, which closed September 12, saw one Cholestech share exchanged for 0.43642 IMI shares. The deal was completed through the merger of one of IMI's wholly-owned subsidiaries with and into Hayward, California-based Cholestech. This is IMI's fifth purchase of the year; it most recently closed a deal for protein-based diagnostics specialist Matritech (see Clinica No 1271, p 3).

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049739

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel